Project Grant R01HL174554
Award Date
8/1/25
Completion Date
5/31/30
Dollars Obligated
$739K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,614,450.00 to The Regents of the University of California, San Francisco to develop and translate hyperpolarized 13C-pyruvate MRI technology for evaluating metabolic remodeling in heart disease. The key goals are to: Develop hyperpolarized 13C-pyruvate MRI methods to assess metabolic flexibility and glycolysis-glucose oxidation coupling under different...
This federal Project Grant award, worth $827,356.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports a prospective study to determine the imaging response to immune suppressant therapy in patients with active cardiac sarcoidosis. The study aims to establish quantitative thresholds for imaging parameters, such as FDG uptake on PET and advanced cardiac MRI measures, that are associated with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology to isolate and quantify the contributions of passive and active remodeling events to left ventricular diastolic dysfunction (LVDD). The total award amount is $702,534, with a project period from March 6, 2025 to December 31, 2029. The awardee,...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $758,862 to Yale University to develop a multi-modality imaging approach for guiding the delivery of therapeutic hydrogels to the heart for prevention of remodeling after myocardial infarction (MI). The project aims to employ hybrid SPECT/CT imaging to non-invasively track markers of inflammation and fibroblast activation, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $756,947 to the University of Utah to develop and test new cardiac MRI methods for quantitative assessment of myocardial fibrosis without using gadolinium contrast. The key objectives are to: 1) Study the value of different T1rho MRI techniques and conventional MRI in preclinical models with diffuse or focal fibrosis, 2) Develop and validate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $260,586 to the University of Wisconsin-Madison over a 5-year period starting September 1, 2024. The objective is to develop and optimize a novel positron emission tomography (PET) probe that can monitor extracellular matrix deposition and disease activity in idiopathic pulmonary fibrosis (IPF), a fatal lung disease characterized by...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...